eXmoor Pharma News and Resources

eXmoor Pharma, a UK-based CDMO with embedded consultancy capabilities, has announced a collaboration with France’s Signadori Bio to accelerate the development of gene-modified monocyte-derived macrophage therapies for solid tumours. The partnership will focus on advancing Signadori Bio’s lead candidate—developed at

eXmoor Pharma, a cell and gene therapy CDMO with embedded consultancy expertise, has entered a strategic partnership with KU Leuven to accelerate novel gene therapy programmes from academic research to first-in-human trials. The collaboration supports KU Leuven’s new cell and

eXmoor Pharma has reached a key milestone by obtaining a Manufacturing and Import Authorization for Investigational Medicinal Products (MIA(IMP)) license from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This authorization permits the company to produce good manufacturing practice